Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases, Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2009
End Date:November 2012

Use our guide to learn which trials are right for you!

A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)


The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid
arthritis (RA) patients who have an inadequate response to their current treatment with
either etanercept + methotrexate or adalimumab + methotrexate to treatment with golimumab 50
mg subcutaneous injection (a needle inserted under your skin in the back of your upper arm,
upper thigh or stomach area) every 4 weeks + methotrexate. This study is also designed to
evaluate the benefit and safety of switching patients from treatment with golimumab 50 mg
subcutaneous injection every 4 weeks + methotrexate to golimumab 2 mg/kg intravenous every 8
weeks + methotrexate, for those who do not achieve a marked improvement of their RA at Week
16.


The main purpose of this study is to assess the effects (good and bad) of golimumab for
rheumatoid arthritis (RA) in patients previously treated with another tumor necrosis factor
(TNF) inhibitor. Golimumab is a type of TNF inhibitor. TNF is a naturally occurring
substance in the body and this substance may cause long-term inflammation. Golimumab may
help fight your disease by blocking the activity of TNF in your body. This study will assess
the safety of golimumab and determine if there is a reduction of the pain and swelling in
the joints of patients with rheumatoid arthritis treated with golimumab. The effect of
golimumab on physical function, and the quality of life in patients with rheumatoid
arthritis will also be assessed. Golimumab will be given by a subcutaneous injection (SC)
every 4 weeks at doses of 50 mg and possibly by intravenous injection (IV) every 8 weeks at
2 mg/kg. Golimumab is given by a SC injection with a needle inserted under your skin in the
back of your upper arm, your upper thigh, stomach area or by IV in your arm. If you are
eligible to take part in this study, you will initiate treatment with open-label golimumab
SC injections every 4 weeks. During the first 12 weeks you and your doctor will know what
medication you are receiving, this is called open-label. Starting at Week 16, depending on
how your RA has improved, you will be put into one of three groups where each group gets a
different treatment. If your study doctor sees an improvement of in your disease you can
continue to receive an injection of golimumab 50 mg SC every 4 weeks through Week 48. If
your disease has not improved you will be randomly placed into one of two study groups. You
will have approximately a one in three chance of being put in the group receiving golimumab
50mg SC every four weeks along with placebo drug IV every eight weeks and a two in three
chance of being put in the group receiving 2mg/kg IV every eight weeks along with placebo SC
every four weeks. Starting with Week 16 if you are placed in Group 1, the study will remain
open labeled. If you are randomized to Groups 2a or 2b, the study is "blinded." This means
that neither you nor your study doctor will know in which group you are placed. However, if
needed for safety or health reasons, your study doctor can find out your treatment at any
time. Placebo is an inactive treatment that looks the same as the study drug golimumab, but
does not contain any active medication. Your disease will be measured by your physician
using standards called American College of Rheumatology (ACR) 20 and Disease Activity Score
(DAS) 28. For example, if a study reported that 55% of patients achieved ACR20, that means
55% of patients in the study achieved a 20% improvement in tender or swollen joint counts as
well as 20% improvement in three of the other five criteria. DAS28 is based on counts of
the number of painful joints and the number of swollen joints you have out of 28 joints.
All patients will receive golimumab 50 mg subcutaneous injection every 4 weeks +
methotrexate for 16 weeks. Patients whose disease shows pronounced improvement will continue
to receive this therapy every 4 weeks for 36 more weeks. Patients who do not achieve a
DAS-28 "good" response, as defined by EULAR criteria, will receive either golimumab 50 mg
subcutaneous injection every 4 weeks + methotrexate for 36 more weeks OR golimumab 2 mg/kg
IV every 8 weeks + methotrexate for 34 more weeks.


We found this trial at
33
sites
Metairie, Louisiana
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Atlanta, Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bettendorf, Iowa 52722
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Coeur D'Alene, Idaho
?
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Jackson, Mississippi
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Jeffersonville, Indiana
?
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Kansas City, Kansas
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
?
mi
from
Lima, OH
Click here to add this to my saved trials
Little Rock, Arkansas
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Louisville, Kentucky
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Milwaukee, Wisconsin
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Morgantown, West Virginia
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Nashville, Tennessee
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Omaha, Nebraska
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ponca City, Oklahoma
?
mi
from
Ponca City, OK
Click here to add this to my saved trials
Richmond, Virginia
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
St Louis, Missouri
?
mi
from
St Louis, MO
Click here to add this to my saved trials
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials